Analyst Price Targets — RARE
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 13, 2026 12:05 pm | — | Wedbush | $30.00 | $31.94 | TheFly | Ultragenyx price target raised to $30 from $26 at Wedbush |
| July 7, 2026 11:28 am | — | RBC Capital | $40.00 | $33.70 | TheFly | Ultragenyx price target raised to $40 from $35 at RBC Capital |
| May 8, 2026 1:36 pm | — | Wedbush | $26.00 | $26.17 | TheFly | Ultragenyx price target lowered to $26 from $27 at Wedbush |
| May 8, 2026 11:14 am | — | Guggenheim | $43.00 | $26.13 | TheFly | Ultragenyx price target lowered to $43 from $52 at Guggenheim |
| April 29, 2026 9:43 am | Eliana Merle | Barclays | $43.00 | $24.53 | TheFly | Ultragenyx price target lowered to $43 from $44 at Barclays |
| April 16, 2026 12:31 pm | — | Morgan Stanley | $67.00 | $25.02 | TheFly | Ultragenyx price target raised to $67 from $50 at Morgan Stanley |
| March 12, 2026 2:39 pm | Joseph Schwartz | Leerink Partners | $60.00 | $21.36 | StreetInsider | Leerink Partners Reiterates Outperform Rating on Ultragenyx Pharma (RARE): "encouraged by this clinical win" |
| February 18, 2026 1:17 pm | Gavin Clark-Gartner | Evercore ISI | $34.00 | $20.14 | TheFly | Ultragenyx price target lowered to $34 from $37 at Evercore ISI |
| February 17, 2026 12:49 pm | — | Evercore ISI | $37.00 | $20.52 | TheFly | Ultragenyx price target lowered to $37 from $39 at Evercore ISI |
| February 17, 2026 11:11 am | Raghuram Selvaraju | H.C. Wainwright | $50.00 | $20.52 | TheFly | Ultragenyx price target lowered to $50 from $60 at H.C. Wainwright |
Latest News for RARE
SAN DIEGO, July 15, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of current, long-term shareholders of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) against certain of its officers and directors for alleged breaches of fiduciary duty.
NOVATO, Calif., July 08, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) released its 2025 Impact Report, detailing the company's work on behalf of patients and families living with rare and ultra-rare diseases. In 2025, Ultragenyx advanced five investigational therapies in pivotal clinical programs with the potential to reach tens of thousands of patients around the world — while continuing…
Ultragenyx (RARE) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Ultragenyx (RARE) is transitioning from a broad pipeline to a focused rare disease platform, entering a high-catalyst period with four approved products and multiple late-stage assets. Despite a recent Phase 3 failure and Q1 2026 net loss, RARE reaffirmed 2026 revenue guidance of $730–$760 million, supported by a scalable commercial base and cost controls. Key near-term catalysts include FDA reviews for DTX401 and…
NOVATO, Calif., June 19, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 44,409 restricted stock units of the company's common stock to 15 newly hired non-executive officers of the company. The awards were approved by the compensation…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for RARE.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.